Acyclovir: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
*Acyclic guanosine analog that competes with deoxyguanosine triphosphate to inhibit viral DNA polymerase |
*Acyclic guanosine analog that competes with deoxyguanosine triphosphate to inhibit viral DNA polymerase |
||
*Resistance mediated by mutation in or decrease of thymidine kinase |
*Resistance mediated by mutation in or decrease of thymidine kinase |
||
*Good penetration into CNS and vitreous if administered intravenously, though not orally |
|||
*Adverse drug reactions include: |
*Adverse drug reactions include: |
||
**[[Adverse drug reaction::Acute kidney injury]] from crystal deposition, so maintain hydration |
**[[Adverse drug reaction::Acute kidney injury]] from crystal deposition, so maintain hydration |
||
Revision as of 17:11, 13 February 2021
- Acyclic guanosine analog that competes with deoxyguanosine triphosphate to inhibit viral DNA polymerase
- Resistance mediated by mutation in or decrease of thymidine kinase
- Good penetration into CNS and vitreous if administered intravenously, though not orally
- Adverse drug reactions include:
- Acute kidney injury from crystal deposition, so maintain hydration
- Phlebitis
- Neurotoxicity, with lethargy, confusion, tremor, myoclonus, agitation, hallucinations, and extrapyramidal symptoms
